ADHD Diagnosis and Drug Use Estimates in France: A Case for Using Health Care Insurance Data - a response to Drs. Ramus and Peyre

Lecendreux M. Konofal E. Faraone S. V. (2011). Prevalence of attention deficit hyperactivity disorder and associated features among children in France. Journal of Attention Disorders, 15(6), 516–524. https://doi.org/10.1177/1087054710372491

National Agency for Medicines and Health Products Safety. (2013). Méthylphénidate: données d’utilisation et de sécurité d’emploi en France. https://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/Donnees-d-utilisation-et-mesures-visant-a-securiser-l-emploi-du-methylphenidate-en-France-publication-par-l-ANSM-d-un-rapport-d-analyse-et-d-une-brochure-d-information-a-destination-des-patients-et-de-leur-entourage-Point-d-information

National Agency for Medicines and Health Products Safety. (2017). Méthylphénidate: données d’utilisation et de sécurité d’emploi en France. https://www.ansm.sante.fr/S-informer/Points-d-information-Points-d-information/Methylphenidatedonnees-d-utilisation-et-de-securite-d-emploi-en-FrancePoint-d-Information

Olfson M. Gameroff M. J. Marcus S. C. Jensen P. S. (2003). National trends in the treatment of attention deficit hyperactivity disorder. American Journal of Psychiatry, 160, 1071–1077.

Schmidt-Troschke S. O. Ostermann T. Melcher D. Schuster R. Erben C. M. Matthiessen P. F. (2004). The use of methylphenidate in children: Analysis of prescription usage based in routine data of the statutory health insurance bodies concerning drug prescriptions. Gesundheitswesen, 66, 387–392.